Exstent appoints Matt Thompson as CEO to drive global growth in personalized aortic support
November 13, 2025 London, UK — Exstent, a UK-based medical device company developing personalized external aortic support to preserve the native aorta, today announced the appointment of Matt Thompson as chief executive officer to lead its next phase of global growth.
Matt brings more than two decades of combined clinical and commercial leadership to Exstent. He previously held leadership roles, including president and CEO, at Endologix, guiding the company through transformation, portfolio growth and the 2021 acquisition of PQ Bypass. Earlier in his career, Matt was professor of vascular surgery at St George’s Hospital, University of London, and Consultant Vascular Surgeon at St George’s Vascular Institute. His experience in integrating novel vascular technologies into established commercial frameworks aligns closely with Exstent’s strategic direction.
“Exstent’s personalized external aortic support is a meaningful advance in managing ascending aortic disease,” Thompson said. “It preserves the native anatomy and offers a less invasive alternative to open graft replacement. My focus is to build on the company’s strong clinical foundation, expand access through collaboration and position Exstent for sustainable growth.”
Exstent’s flagship innovation, Exovasc, is a custom-made external support designed to reinforce the body’s major blood vessels and prevent dilation and dissection. Now used in more than 40 leading cardiac centers across the UK, Europe, Australia and beyond, over 1,500 patients have been treated, with long-term data demonstrating excellent safety, valve preservation and durability. Exstent is preparing for broader clinical adoption through strategic partnerships and scaled manufacturing.
Peter Phillips, chair of Exstent, added: “Exstent is entering a significant phase of expansion. Matt’s clinical expertise and commercial leadership will be instrumental as we move from strong foundations to broader adoption. We look forward to working with partners who share our commitment to improving outcomes in aortic disease.”
Media Enquiries: Cynthia Azucena([email protected])
Website: www.exstent.com
About Us
Established in 2002, Exstent was created with a clear purpose — to develop safer, more personalized solutions for people living with aortic conditions. From the outset, our focus has been on reducing surgical risk and preserving the body’s natural anatomy.
The company’s origins trace back to engineer and patient Tal Golesworthy, whose experience with Marfan syndrome inspired the development of the Exovasc personalized external support. In 2004, Tal became the first person in the world to receive the device he helped design.
Today, Exstent continues to advance innovation in personalized aortic care, helping patients live with confidence — free from lifelong medication and repeat surgery. Every step forward is guided by our commitment to improving both outcomes and quality of life.